Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Inclusion Criteria: -

- Completion of Study RAP-MD-30, RAP-MD-31, or RAP-MD-32

- If female of childbearing potential, have a negative serum β-human chorionic
gonadotropin (β-hCG) pregnancy test

Exclusion Criteria: -

- DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of
treatment within 6 months before Visit 1

- Lifetime history of meeting DSM-5 criteria for:

- 1.Schizophrenia spectrum or other psychotic disorder

- 2.Bipolar or related disorder

- 3.Major neurocognitive disorder

- 4.Neurodevelopmental disorder of greater than mild severity or of a severity that
impacts the participant's ability to consent, follow study directions, or otherwise
safely participate in the study

- 5.Dissociative disorder

- 6.Posttraumatic stress disorder

- 7.MDD with psychotic features

- Significant suicide risk, as judged by the Investigator